Cardiac sodium channels and inherited electrophysiological disorders: An update on the pharmacotherapy

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 13, 2014, Pages 1875-1887

  Van Hoeijen, Daniel A ^a   Blom, Marieke T ^a   Tan, Hanno L ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Brugada syndrome; Cardiac arrhythmias; Cardiac sodium channel; Long QT syndrome type 3; Pharmacotherapy

Indexed keywords

ANTIARRHYTHMIC AGENT; SODIUM CHANNEL;

ACTION POTENTIAL; ARRHYTHMIAS, CARDIAC; BRUGADA SYNDROME; GENETICS; HEART MUSCLE; HUMAN; LONG QT SYNDROME; METABOLISM; MUTATION; PHYSIOLOGY;

ACTION POTENTIALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; BRUGADA SYNDROME; HUMANS; LONG QT SYNDROME; MUTATION; MYOCARDIUM; SODIUM CHANNELS;

EID: 84905842771     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.936380     Document Type: Review

References (87)

1. Smits JP, Blom MT, Wilde AA, et al. Cardiac sodium channels and inherited electrophysiologic disorders: a pharmacogenetic overview. Expert Opin Pharmacother 2008;9(4):537-49
2. Venetucci L, Denegri M, Napolitano C, et al. Inherited calcium channelopathies in the pathophysiology of arrhythmias. Nat Rev Cardiol 2012;9(10):561-75
3. Giudicessi JR, Ackerman MJ. Potassium-channel mutations and cardiac arrhythmias-diagnosis and therapy. Nat Rev Cardiol 2012;9(6):319-32
4. Ruan Y, Liu N, Priori SG. Sodium channel mutations and arrhythmias. Nat Rev Cardiol 2009;6(5):337-48
5. Adsit GS, Vaidyanathan R, Galler CM, et al. Channelopathies from mutations in the cardiac sodium channel protein complex. J Mol Cell Cardiol 2013;61:34-43
6. Wilde AA, Brugada R. Phenotypical manifestations of mutations in the genes encoding subunits of the cardiac sodium channel. Circ Res 2011;108(7):884-97
7. Schwartz PJ, Ackerman MJ, George AL Jr, et al. Impact of genetics on the clinical management of channelopathies. J Am Coll Cardiol 2013;62(3):169-80
8. Tan HL. Sodium channel variants in heart disease: expanding horizons. J Cardiovasc Electrophysiol 2006;17(Suppl 1):S151-S57
9. Amin AS, Tan HL, Wilde AA. Cardiac ion channels in health and disease. Heart Rhythm 2010;7(1):117-26
10. Amin AS, Asghari-Roodsari A, Tan HL. Cardiac sodium channelopathies. Pflugers Arch 2010;460:223-37
11. Remme CA, Verkerk AO, Nuyens D, et al. Overlap syndrome of cardiac sodium channel disease in mice carrying the equivalent mutation of human SCN5A-1795insD. Circulation 2006;114(24):2584-94
12. Bezzina CR, Barc J, Mizusawa Y, et al. Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death. Nat Genet 2013;45(9):1044-9
13. Hoshi M, Du XX, Shinlapawittayatorn K, et al. Brugada syndrome disease phenotype explained in apparently benign sodium channel mutations. Circ Cardiovasc Genet 2014;7(2):123-31
14. Keller DI, Rougier JS, Kucera JP, et al. Brugada syndrome and fever: genetic and molecular characterization of patients carrying SCN5A mutations. Cardiovasc Res 2005;67(3):510-19
15. Dumaine R, Towbin JA, Brugada P, et al. Ionic mechanisms responsible for the electrocardiographic phenotype of the brugada syndrome are temperature dependent. Circ Res 1999;85(9):803-9
16. Amin AS, Meregalli PG, Bardai A, et al. Fever increases the risk for cardiac arrest in the Brugada syndrome. Ann Intern Med 2008;149(3):216-18
17. Bardai A, Amin AS, Blom MT, et al. Sudden cardiac arrest associated with use of a non-cardiac drug that reduces cardiac excitability: evidence from bench, bedside, and community. Eur Heart J 2013;34(20):1506-16
18. Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm 2013;10(12):1932-63
19. Näbauer M, Beuckelmann D, Uberfuhr P, et al. Regional differences in current density and rate-dependent properties of the transient outward current in subepicardial and subendocardial myocytes of human left ventricle. Circulation 1996;93:168-77
20. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol 1992;20(6):1391-6
21. Wilde AA. Proposed diagnostic criteria for the Brugada syndrome: consensus report. Circulation 2002;106(19):2514-19
22. Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 2005;111(5):659-70
23. Chen Q, Kirsch GE, Zhang D, et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 1998;392:293-6
24. Inherited arrhtyhmias database. 2000. Available from: http://www.fsm.it/cardmoc/[Cited 11 April 2014]
25. Kapplinger JD, Tester DJ, Alders M, et al. An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm 2010;7(1):33-46
26. Deschenes I, Baroudi G, Berthet M, et al. Electrophysiological characterization of SCN5A mutations causing long QT (E1784K) and Brugada (R1512W and R1432G) syndromes. Cardiovasc Res 2000;46:55-65
27. Valdivia CR, Ackerman MJ, Testerb DJ, et al. A novel SCN5A arrhythmia mutation, M1766L, with expression defect rescued by mexiletine. Cardiovasc Res 2002;55:279-89
28. Valdivia CR, Tester DJ, Rok BA, et al. A trafficking defective, Brugada syndrome-causing SCN5A mutation rescued by drugs. Cardiovasc Res 2004;62(1):53-62
29. Herfst LJ, Rook MB, Jongsma HJ. Trafficking and functional expression of cardiac Na+ channels. J Mol Cell Cardiol 2004;36(2):185-93
30. Pfahnl AE, Viswanathan PC, Weiss R, et al. A sodium channel pore mutation causing Brugada syndrome. Heart Rhythm 2007;4(1):46-53
31. Baranchuk A, Nguyen T, Ryu MH, et al. Brugada phenocopy: new terminology and proposed classification. Ann Noninvasive Electrocardiol 2012;17(4):299-314
32. Hoogendijk MG, Opthof T, Postema PG, et al. The Brugada ECG pattern: a marker of channelopathy, structural heart disease, or neither? Toward a unifying mechanism of the Brugada syndrome. Circ Arrhythm Electrophysiol 2010;3(3):283-90
33. Yan GX, Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation 1999;100(15):1660-6
34. Antzelevitch C. Heterogeneity and cardiac arrhythmias: an overview. Heart Rhythm 2007;4(7):964-72
35. Wilde AA, Postema PG, Di Diego JM, et al. The pathophysiological mechanism underlying Brugada syndrome: depolarization versus repolarization. J Mol Cell Cardiol 2010;49(4):543-53
36. Szel T, Antzelevitch C. Abnormal repolarization as the basis for late potentials and fractionated electrograms recorded from epicardium in experimental models of Brugada syndrome. J Am Coll Cardiol 2014;63(19):2037-45
37. Coronel R, Casini S, Koopmann TT, et al. Right ventricular fibrosis and conduction delay in a patient with clinical signs of Brugada syndrome: a combined electrophysiological, genetic, histopathologic, and computational study. Circulation 2005;112(18):2769-77
38. Postema PG, van Dessel PF, de Bakker JM, et al. Slow and discontinuous conduction conspire in Brugada syndrome: a right ventricular mapping and stimulation study. Circ Arrhythm Electrophysiol 2008;1(5):379-86
39. Catalano O, Antonaci S, Moro G, et al. Magnetic resonance investigations in Brugada syndrome reveal unexpectedly high rate of structural abnormalities. Eur Heart J 2009;30(18):2241-8
40. van Hoorn F, Campian ME, Spijkerboer A, et al. SCN5A mutations in Brugada syndrome are associated with increased cardiac dimensions and reduced contractility. PLoS One 2012;7(8):e42037
41. Schott JJ, Alshinawi C, Kyndt F, et al. Cardiac connduction defects associate with mutations in SCN5A. Nat Genet 1999;23(1):20-1
42. Benson DW, Wang DW, Dyment M, et al. Congenital sick sinus syndrome caused by recessive mutations in the cardiac sodium channel gene (SCN5A). J Clin Invest 2003;112(7):1019-28
43. Groenewegen WA. A cardiac sodium channel mutation cosegregates with a rare connexin40 genotype in familial atrial standstill. Circ Res 2002;92(1):14-22
44. Ge J, Sun A, Paajanen V, et al. Molecular and clinical characterization of a novel SCN5A mutation associated with atrioventricular block and dilated cardiomyopathy. Circ Arrhythm Electrophysiol 2008;1(2):83-92
45. McNair WP, Ku L, Taylor MR, et al. SCN5A mutation associated with dilated cardiomyopathy, conduction disorder, and arrhythmia. Circulation 2004;110(15):2163-7
46. Kaufman ES. Mechanisms and clinical management of inherited channelopathies: long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, and short QT syndrome. Heart Rhythm 2009;6(8 Suppl):S51-5
47. Romero K, Woosley RL. Clarification to the http://www.qtdrugs.org updated list. Pharmacoepidemiol Drug Saf 2009;18:423-4
48. Postema PG, Wolpert C, Amin AS, et al. Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (http://www.brugadadrugs.org). Heart Rhythm 2009;6(9):1335-41
49. Echt D, Liebson P, Mitchell B, et al. Mortality and morbidity in patients receiving encainide, flecainide or placebo. N Engl J Med 1991;324(12):781-8
50. Greenberg H, Dwyer E, Hochman JS, et al. Interaction of ischaemia and encainide/flecainide treatment: a proposed mechanism for the increased mortality in CAST I. Br Heart J 1995;74:631-5
51. Casini S, Verkerk AO, van Borren MM, et al. Intracellular calcium modulation of voltage-gated sodium channels in ventricular myocytes. Cardiovasc Res 2009;81(1):72-81
52. Viswanathan PC, Bezzina CR, George AL, et al. Gating-dependent mechanisms for flecainide action in SCN5A-linked arrhythmia syndromes. Circulation 2001;104(10):1200-5
53. Theodotou N, Cillo JE Jr. Brugada syndrome (sudden unexpected death syndrome): perioperative and anesthetic management in oral and maxillofacial surgery. J Oral Maxillofac Surg 2009;67(9):2021-5
54. Kloesel B, Ackerman MJ, Sprung J, et al. Anesthetic management of patients with Brugada syndrome: a case series and literature review. Can J Anaesth 2011;58:824-36
55. Bebarta VS, Summers S. Brugada electrocardiographic pattern induced by cocaine toxicity. Ann Emerg Med 2007;49(6):827-9
56. Xu Y-Q, Crumb WJ Jr, Clarkson CW. Cocaethylene, a metabolite of cocaine and etanol, is a potent blocker of cardiac sodium channel. J Pharmacol Exp Ther 1994;271(1):319-25
57. Ohkubo K, Nakai T, Watanabe I. Alcohol-induced ventricular fibrillation in a case of Brugada syndrome. Europace 2013;15(7):1058
58. Veerman CC, Verkerk AO, Blom MT, et al. Slow delayed rectifier potassium current blockade contributes importantly to drug-induced long QT syndrome. Circ Arrhythm Electrophysiol 2013;6(5):1002-9
59. Suzuki H, Torigoe K, Numata O, et al. Infant case with a malignant form of Brugada syndrome. J Cardiovasc Electrophysiol 2000;11:1277-80
60. Watanabe A, Fukushima Kusano K, Morita H, et al. Low-dose isoproterenol for repetitive ventricular arrhythmia in patients with Brugada syndrome. Eur Heart J 2006;27(13):1579-83
61. Ohgo T, Okamura H, Noda T, et al. Acute and chronic management in patients with Brugada syndrome associated with electrical storm of ventricular fibrillation. Heart Rhythm 2007;4(6):695-700
62. Miyazaki T, Mitamura H, Miyoshi S, et al. Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome. J Am Coll Cardiol 1996;27(5):1061-70
63. Kyriazis K, Bahlmann E, van der Schalk H, et al. Electrical storm in Brugada syndrome successfully treated with orciprenaline; effect of low-dose quinidine on the electrocardiogram. Europace 2009;11(5):665-6
64. Alings M, Dekker L, Sadee A, et al. Quinidine induced electrocardiograpic normalization in two patients with Brugada syndrome. Pacing Clin Electrophysiol 2001;24:1420-2
65. Marquez MF, Bonny A, Hernandez-Castillo E, et al. Long-term efficacy of low doses of quinidine on malignant arrhythmias in Brugada syndrome with an implantable cardioverter-defibrillator: a case series and literature review. Heart Rhythm 2012;9(12):1995-2000
66. Belhassen B, Glick A, Viskin S. Efficacy of quinidine in high-risk patients with Brugada syndrome. Circulation 2004;110(13):1731-7
67. Hermida JS, Denjoy I, Clerc J, et al. Hydroquinidine therapy in Brugada syndrome. J Am Coll Cardiol 2004;43(10):1853-60
68. Sharif-Kazemi MB, Emkanjoo Z, Tavoosi A, et al. Electrical storm in Brugada syndrome during pregnancy. Pacing Clin Electrophysiol 2011;34(2):e18-21
69. Mizusawa Y, Sukarada H, Nishizaki M, et al. Effects of low-dose quinidine on ventricular tachyarrhythmias in patients with Brugada syndrome. J Cardiovasc Pharmacol 2006;47:359-64
70. Nakagawa E, Takagi M, Tatsumi H, et al. Succesful radiofrequency catheter ablation for electrical storm of ventricular fibrillation in a patient with Brugada syndrome. Circ J 2008;72:1025-9
71. Viskin S, Wilde AA, Tan HL, et al. Empiric quinidine therapy for asymptomatic Brugada syndrome: time for a prospective registry. Heart Rhythm 2009;6(3):401-4
72. Tsuchiya T, Ashikaga K, Honda T, et al. Prevention of ventricular fibrillation by cilostazol, an oral phosphodiesterase inhibitor, in a patient with Brugada syndrome. J Cardiovasc Electrophysiol 2002;13:698-701
73. Abud A, Bagattin D, Goyeneche R, et al. Failure of cilostazol in the prevention of ventricular fibrillation in a patient with Brugada syndrome. J Cardiovasc Electrophysiol 2006;17:210-12
74. Moreno JD, Clancy CE. Pathophysiology of the cardiac late Na current and its potential as a drug target. J Mol Cell Cardiol 2012;52(3):608-19
75. Moss AJ, Zareba W, Schwarz KQ, et al. Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome. J Cardiovasc Electrophysiol 2008;19(12):1289-93
76. Karwatowska-Prokopczuk E, Wang W, Cheng ML, et al. The risk of sudden cardiac death in patients with non-ST elevation acute coronary syndrome and prolonged QTc interval: effect of ranolazine. Europace 2013;15(3):429-36
77. Antzelevitch C, Burashnikov A, Sicouri S, et al. Electrophysiologic basis for the antiarrhythmic actions of ranolazine. Heart Rhythm 2011;8(8):1281-90
78. Rajamani S, El-Bizri N, Shryock JC, et al. Use-dependent block of cardiac late Na(+) current by ranolazine. Heart Rhythm 2009;6(11):1625-31
79. Shah DP, Baez-Escudero JL, Weisberg IL, et al. Ranolazine safely decreases ventricular and atrial fibrillation in Timothy syndrome (LQT8). Pacing Clin Electrophysiol 2012;35(3):e62-4
80. van den Berg MP, van den Heuvel F, van Tintelen JP, et al. Successful treatment of a patient with symptomatic long QT syndrome type 3 using ranolazine combined with a beta-blocker. Int J Cardiol 2014;171(1):90-2
81. Belardinelli L, Liu G, Smith-Maxwell C, et al. A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias. J Pharmacol Exp Ther 2013;344(1):23-32
82. Sicouri S, Belardinelli L, Antzelevitch C. Antiarrhythmic effects of the highly selective late sodium channel current blocker GS-458967. Heart Rhythm 2013;10(7):1036-43
83. Vacher B, Pignier C, Letienne R, et al. F 15845 inhibits persistent sodium current in the heart and prevents angina in animal models. Br J Pharmacol 2009;156(2):214-25
84. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary. Circulation 2006;114(7):700-52
85. Schilling RJ. Cardioversion of atrial fibrillation: the use of antiarrhythmic drugs. Heart 2010;96(5):333-8
86. Taylor R, Gandhi MM, Lloyd G. Tachycardia due to atrial flutter with rapid 1:1 conduction following treatment of atrial fibrillation with flecainide. BMJ 2010;340:b4684
87. Antzelevitch C. The Brugada Syndrome: ionic basis and arrhythmia mechanisms. J Cardiovasc Electrophysiol 2001;12:268-72 Onderzoek